Generics Bulletin: ジェネリック＆バイオシミラーニュース

India Biosimilars Landscape

19 Aug 2021

India leads the ways with the highest number of approved biosimilars.

Topic Clinical Trials Biosimilars

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Coherus Is Confident After US Ranibizumab Filing

27 Nov 2020

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Topic Biosimilars Deals

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Celltrion's Remsima SC Ready For Early 2020 Launch

27 Nov 2020

Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.

Topic Biosimilars Launches Regulation

ターゲット市場の実像をつかむ

The evolving landscape of biosimilars

27 Nov 2020

It is important to understand how the biosimilar market has developed over the past five years. Take a look at some of the key events here.

Topic Biosimilars

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Alberta Is Second Canadian Province To Switch To Biosimilars

27 Nov 2020

Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

Topic Biosimilars Regulation

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Pfizer Reports 80% Biosimilars Growth In Q3

By Akriti Seth 17 Nov 2020

Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.

Topic Coronavirus Biosimilars Deals